Urinary Tract Infection News and Research RSS Feed - Urinary Tract Infection News and Research

Urinary tract infections are a serious health problem affecting millions of people each year. Infections of the urinary tract are the second most common type of infection in the body. Urinary tract infections (UTIs) account for about 8.3 million doctor visits each year.* Women are especially prone to UTIs for reasons that are not yet well understood. One woman in five develops a UTI during her lifetime. UTIs in men are not as common as in women but can be very serious when they do occur.
Researchers identify way to assess women at increased risk for UTI after pelvic-floor surgery

Researchers identify way to assess women at increased risk for UTI after pelvic-floor surgery

Researchers at Loyola University Chicago Stritch School of Medicine may have identified a way to assess who is at risk for developing a urinary tract infection (UTI) following pelvic-floor surgery. [More]
Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

Alport Syndrome was first described by a physician called Cecil Alport, back in the late 1920s. It's a genetic disease that affects a certain type of collagen involved in the functioning of the kidney, the ear, and the eye. [More]
NPS MedicineWise Reducing Antibiotic Resistance program focuses on urinary tract infections

NPS MedicineWise Reducing Antibiotic Resistance program focuses on urinary tract infections

The next phase of the NPS MedicineWise Reducing Antibiotic Resistance program for health professionals has launched today focused on the complex topic of managing urinary tract infections (UTIs). [More]
Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS. [More]
Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim today announced that Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States. [More]
Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). [More]
Common type of hospital-associated infections can be prevented with vaccine

Common type of hospital-associated infections can be prevented with vaccine

The most common type of hospital-associated infection may be preventable with a vaccine, new research in mice suggests. [More]
No added benefit determined from Mirabegron for mortality, morbidity and quality of life

No added benefit determined from Mirabegron for mortality, morbidity and quality of life

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. [More]
Drugs plus biofeedback show promise for dysfunctional voiding

Drugs plus biofeedback show promise for dysfunctional voiding

Research shows that the use of α1-blockers in combination with uroflowmetry biofeedback is more effective than either treatment alone for improving urinary symptoms and quality of life in women with dysfunctional voiding and recurrent urinary tract infection. [More]
Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite Aid, Kroger and many other leading chain and independent retailers, according to Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. [More]
Risk of urinary tract infections after prostate biopsy highest in men with prior infections

Risk of urinary tract infections after prostate biopsy highest in men with prior infections

Risk of Urinary Tract Infections after Prostate Biopsy Highest in Men with Prior Infections or Significant Comorbidities, Report Swedish Researchers in The Journal Of Urology® [More]
Immunosignaturing holds promise for accurate diagnosis of Valley Fever

Immunosignaturing holds promise for accurate diagnosis of Valley Fever

On July 5, 2011, a massive wall of dust, ("haboob," in Arabic), blanketed Phoenix, Arizona, creating an awesome spectacle, (or stubborn nuisance, depending on your perspective). Dust storms are a common occurrence in the arid desert environments of the American Southwest. [More]
Sixteen cores better than 12 for prostate cancer detection

Sixteen cores better than 12 for prostate cancer detection

Sixteen-core prostate biopsy has a slightly higher cancer detection rate than 12-core biopsy, but with a similar safety profile and no increased detection of clinically insignificant tumours, study findings show. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
Vanda’s HETLIOZ MAA for Non-24-Hour Sleep-Wake Disorder accepted for evaluation by the EMA

Vanda’s HETLIOZ MAA for Non-24-Hour Sleep-Wake Disorder accepted for evaluation by the EMA

Vanda Pharmaceuticals Inc. announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). [More]
Findings explain why women with bladder cancer are often diagnosed at later stage than men

Findings explain why women with bladder cancer are often diagnosed at later stage than men

Women with blood in their urine (hematuria) were less than half as likely as men with the same issue to be referred to a urologist for further tests, according to a new Vanderbilt University study. [More]
European Commission grants Marketing Authorization for empagliflozin for treatment of type 2 diabetes

European Commission grants Marketing Authorization for empagliflozin for treatment of type 2 diabetes

The European Commission has granted Marketing Authorisation for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor from Boehringer Ingelheim and Eli Lilly and Company. [More]
Painkillers may prevent repeated urinary tract infections in women, says study

Painkillers may prevent repeated urinary tract infections in women, says study

Women plagued by repeated urinary tract infections may be able to prevent the infections with help from over-the-counter painkillers, new research in mice shows. [More]
Research may have "major implications" for treatment of urinary tract infections in children

Research may have "major implications" for treatment of urinary tract infections in children

A major new pediatric research study led by a Wayne State University researcher, funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH) and published this week in the New England Journal of Medicine (NEJM), has "major implications" for the treatment of urinary tract infections (UTIs) in millions of American children. [More]
Long-term use of drug combination reduces risk of recurrent urinary tract infection in children

Long-term use of drug combination reduces risk of recurrent urinary tract infection in children

Long-term use of a drug combination reduces the risk of recurrent urinary tract infection by up to 80 percent in children with the urinary condition vesicoureteral reflux compared to placebo, according to research funded by the National Institutes of Health. [More]